Blog Section

Ansun BioPharma Announces CDC Publication Showing Potent Inhibitory Effects of DAS181 on EnteroVirus68

San Diego – September 28, 2015 – Ansun Biopharma announced today the publication of a report by researchers at the Centers for Disease Control demonstrating the strong inhibition of Enterovirus68 (EV68) by DAS181. The report published in the peer reviewed journal, Antimicrobial Agents and Chemotherapy, entitled “In Vitro Efficacy of antiviral compounds against enterovirus D68”, examined numerous compounds against the circulating strains of EV68, a virus which caused a large outbreak of severe respiratory disease in the U.S. in 2014. Many infected patients required intensive care and in some patients developed a paralytic disease and some deaths were also attributed to the virus. Currently there are no treatments available for EV68 infection. Of the 15 drugs tested in-vitro, DAS181 was observed to be one of the most potent inhibitors of the virus.  “These data, as well as data from our ongoing and previous studies of influenza and parainfluenza, provide proof of concept that DAS181 may be used against many different respiratory viruses,” suggested Dr. Ronald Moss, CEO of Ansun Biopharma. “Because no treatment options exist, it is imperative that clinical studies examine the effect of DAS181 against EV68, which caused significant morbidity and mortality just last year,” noted Dr. Moss.

The abstract can be found on line at:

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. For more information, please visit or using the identifier NCT01644877.

Leave a Reply

Your email address will not be published. Required fields are marked *